ProQR Therapeutics N.V.
PRQR
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentoā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.21
Price+5.24%
$0.11
1Y
Price
Market Cap
$232.813m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-354.5%
EBITDA Margin-377.6%
Net Profit Margin-425.5%
Free Cash Flow MarginRevenue
$15.558m
-17.7%
1y CAGR+84.6%
3y CAGR+105.8%
5y CAGREarnings
-$42.569m
-53.3%
1y CAGR+1.4%
3y CAGR-0.4%
5y CAGREPS
-$0.43
-26.5%
1y CAGR+12.6%
3y CAGR+10.8%
5y CAGRBook Value
$57.071m
$124.349m
Assets$67.278m
Liabilities$16.491m
DebtDebt to Assets
13.3%
-0.4x
Debt to EBITDAFree Cash Flow
-$49.409m
-30.7%
1y CAGR-63.0%
3y CAGR-87.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in EUR.No items found.
Press Releases
Statements and updates from the company